Visby Medical, a leading innovator in at-home PCR testing of infectious diseases, has announced a strategic collaboration with Watchmaker Genomics, a supplier of innovative products for molecular analysis, to develop next-generation diagnostic tests for respiratory pathogen detection in the at-home setting. This partnership pairs Visby Medical’s instrument-free PCR testing technology – the first and only of its kind – with Watchmaker’s expertise in engineering enzymes to address application-specific performance gaps.
Clinical samples collected from patients for at-home testing are typically unprocessed, making them vulnerable to molecular inhibitors that can reduce signal strength and lower assay sensitivity. The need for rapid results in the at-home setting also places unique performance demands on the assays and the enzymes they rely on.
“Recent increases in COVID cases involving new strains and the current flu season highlight the need for tests that are reliable and fast,” explained Gary Schoolnik, MD, infectious disease expert, Chief Medical Officer at Visby Medical, and Professor of Medicine at Stanford University. “Every patient and their healthcare professional needs test results they can have confidence in so that appropriate treatment decisions can be made quickly for optimal recovery, infection control, and the judicious use of antibiotics. The essential tool is rapid PCR testing that does not require instruments or extended lab preparation.”
“This partnership underscores Watchmaker’s commitment to delivering solutions that address real issues in clinically relevant applications, and we are excited to work with Visby Medical to provide a unique and urgently needed solution that utilizes their PCR platform,” stated Trey Foskett, Co-Founder, and CEO of Watchmaker Genomics. “Our StellarScript HT+ Reverse Transcriptase is engineered to be highly inhibitor-tolerant and thermostable – the novel enzyme is an excellent fit for rapid pathogen detection.”
For more information about Visby Medical and its rapid diagnostic solutions, visit visby.com. Learn more about Watchmaker Genomics and their Precision Enzyme and NGS portfolios by visiting watchmakergenomics.com.
About Watchmaker Genomics
Watchmaker Genomics applies advanced enzymology to enable breakthrough applications for the reading, writing, and editing of DNA and RNA. The company combines domain expertise in protein engineering with large-scale enzyme manufacturing to address the demanding quality, performance, and scale requirements of high-growth clinical genomics applications. Watchmaker's product portfolio includes enzymes and kits for next-generation sequencing, synthetic biology, and molecular diagnostics. For more information, please visit watchmakergenomics.com, follow Watchmaker Genomics on Twitter @WatchmakerGeno1 or find us on LinkedIn.
About Visby Medical
Founded in 2012, Visby Medical is revolutionizing infectious disease diagnosis by empowering users to accurately test for infections anywhere, anytime, with laboratory accuracy. The company’s proprietary technology platform delivers true PCR results in under 30 minutes through the world’s first instrument-free, single-use PCR tests that fit in the palm of your hand. Currently, Visby Medical offers FDA-cleared tests for sexually transmitted infections (STIs) directly to consumers in the comfort of their own home. Visby Medical is actively expanding its platform targeting other critical respiratory and sexual health pathogens. For more information, visit visby.com. Follow Visby Medical on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260205116798/en/
© Business Wire, Inc.
Disclaimer :
This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact person/entity mentioned in the text of the press release.